In a structurally normal heart, do premature ventricular contractions (PVCs) or premature atrial contractions (PACs) cause any problems?

PVCs and PACs in a Structurally Normal Heart: Generally Benign but Require Evaluation

In a structurally normal heart, isolated PVCs and PACs are generally benign and do not cause problems, but the key is confirming the heart is truly structurally normal and monitoring for high PVC burden (>15-20% of beats) which can cause reversible cardiomyopathy. 1

The Critical Distinction: Simple vs. Frequent Ectopy

Simple/Isolated PVCs and PACs

• Simple ventricular ectopy in the absence of heart disease has not been demonstrated to have adverse prognostic significance 1
• PACs occur in nearly all individuals and were historically considered benign 2
• The primary objective when finding ectopy is to exclude any associated functional or structural heart disease, where PVCs may have prognostic significance 1

When PVCs Become Problematic

PVC burden matters significantly. The evidence shows a clear threshold effect:

• PVC burden >15-20% of total beats can produce reversible left ventricular dysfunction (PVC-induced cardiomyopathy) 3
• Even in structurally normal hearts, PVC burden ≥20% causes measurable hemodynamic changes: decreased LV outflow tract velocity, reduced stroke volume index, and increased end-systolic dimension 4
• Among athletes with ≥2,000 PVCs per 24 hours, up to 30% were found to have underlying structural heart disease, compared with 3% in those with <2,000 and 0% in those with <100 PVCs per day 5

Emerging Evidence on Cardiovascular Risk

Recent high-quality meta-analysis data challenges the "completely benign" narrative:

Frequent PVCs (≥500/day) are associated with significantly increased risks 6:

• Atrial fibrillation: HR 1.69 (95% CI 1.39-2.05)
• Heart failure: HR 1.73 (95% CI 1.50-2.00)
• Stroke: HR 1.28 (95% CI 1.10-1.50)
• All-cause mortality: HR 1.31 (95% CI 1.10-1.56)
• Each 1% increment in PVC burden increases atrial fibrillation risk by 5.4% 6

Similarly, frequent PACs are increasingly recognized as associated with developing atrial fibrillation, not the benign finding previously assumed 2

Practical Clinical Approach

Initial Evaluation Algorithm

When PVCs or PACs are detected:

1. Quantify the burden: 24-hour Holter monitoring (or longer with modern leadless recorders) 5
2. Exclude structural heart disease: Echocardiogram is essential 5, 7
3. Exercise stress test: Assess if PVCs suppress with exercise (favorable sign) 5
4. Screen for reversible causes: Electrolyte abnormalities, hyperthyroidism, stimulant use 2, 7

Risk Stratification by PVC Burden

Low burden (<100 PVCs/24h):

• Reassurance if echo normal and PVCs suppress with exercise
• No further evaluation needed if asymptomatic 5

Moderate burden (100-2,000 PVCs/24h):

• Periodic echocardiography to monitor for LV dysfunction 6
• Consider rhythm monitoring for atrial fibrillation detection 6

High burden (>2,000 PVCs/24h or >15-20% of beats):

• Aggressive evaluation: Consider cardiac MRI to exclude early cardiomyopathy (especially ARVC if LBBB morphology with QRS >160ms) 5
• Serial echocardiograms to detect declining LV function 3
• Strong consideration for treatment even if asymptomatic, given risk of PVC-induced cardiomyopathy 3

Treatment Indications

The 2017 AHA/ACC/HRS guidelines provide clear direction 3, 8:

For symptomatic PVCs in structurally normal heart:

• First-line: Beta blocker or non-dihydropyridine calcium channel blocker (Class I recommendation) 8
• Second-line: Antiarrhythmic medication if first-line ineffective/not tolerated (Class IIa) 8
• Catheter ablation: Class I recommendation if medications ineffective, not tolerated, or not patient's preference 3

For PVC-induced cardiomyopathy (declining LV function with high PVC burden):

• Catheter ablation: Class I recommendation - 80% success rate with 82% normalization of LV function within 6 months 3
• Pharmacologic treatment (beta blocker, amiodarone): Class IIa recommendation 3

Critical Pitfalls to Avoid

1. Don't assume "structurally normal" without imaging: Always obtain echocardiogram, especially with frequent or multifocal PVCs 1, 7

2. Don't use antiarrhythmic suppression to reduce mortality: Class I antiarrhythmics (flecainide, quinidine) and d-sotalol increase mortality in post-MI and reduced LVEF patients 3

3. Don't dismiss frequent PVCs as benign: Even in "normal" hearts, high burden causes hemodynamic consequences and increases cardiovascular risk 6, 4

4. Don't wait for symptoms to develop: PVC-induced cardiomyopathy can be insidious - monitor LV function serially in patients with >15-20% PVC burden 3

5. In athletes with ≥2 PVCs on ECG: Minimum workup includes Holter, echo, and exercise stress test - this is not optional 5

Bottom Line for PACs

While less extensively studied than PVCs, frequent PACs warrant attention given their association with incident atrial fibrillation 2. After excluding reversible causes, symptomatic PACs can be treated with beta blockers, with ablation reserved for refractory cases 2.